An Open-Label, Randomized, Parallel Group Study to Investigate the Influence of Renal Impairment on the Efficacy and Safety of Two Doses of Bludigo™ (Indigotindisulfonate Sodium Injection, USP) 0.8% When Used As an Aid in the Determination of Ureteral Patency
Latest Information Update: 05 Mar 2025
At a glance
- Drugs Indigotindisulfonate sodium (Primary)
- Indications Kidney disorders
- Focus Diagnostic use
- Sponsors Provepharm
Most Recent Events
- 28 Feb 2025 Planned End Date changed from 30 Jun 2025 to 1 Jan 2026.
- 28 Feb 2025 Planned primary completion date changed from 30 Jun 2025 to 1 Dec 2025.
- 30 Jan 2024 Status changed from not yet recruiting to recruiting.